keyword
MENU ▼
Read by QxMD icon Read
search

Buprenorphine and adherence

keyword
https://www.readbyqxmd.com/read/28829626/transitioning-from-methadone-to-buprenorphine-maintenance-in-management-of-opioid-use-disorder-during-pregnancy
#1
Shakevia Johnson, Peter R Martin
BACKGROUND: Opioid use disorder during pregnancy is a growing health concern. Methadone maintenance is the treatment of choice but emerging data indicate buprenorphine is a viable alternative. Due to costs and limited accessibility of methadone, pregnant women may require transition from methadone to buprenorphine for maintenance treatment. OBJECTIVES: To assess safety and effectiveness of transitioning from methadone to buprenorphine when necessary during pregnancy...
August 22, 2017: American Journal of Drug and Alcohol Abuse
https://www.readbyqxmd.com/read/28817294/heterogeneity-of-nonadherent-buprenorphine-patients-subgroup-characteristics-and-outcomes
#2
Charles Ruetsch, Joseph Tkacz, Vijay R Nadipelli, Brenna L Brady, Naoko Ronquest, Hyong Un, Joseph Volpicelli
OBJECTIVES: To examine patient characteristics and outcomes associated with nonadherence to buprenorphine and to identify specific patterns of nonadherent behavior. STUDY DESIGN: Cross-sectional, retrospective analysis of health claims data. METHODS: Aetna's administrative claims data were used to categorize incident opioid use disorder (OUD) patients based on buprenorphine medication possession ratio (MPR) into adherent (n = 172) and nonadherent (n = 305) groups...
June 1, 2017: American Journal of Managed Care
https://www.readbyqxmd.com/read/28799677/text-message-reminders-for-improving-patient-appointment-adherence-in-an-office-based-buprenorphine-program-a-feasibility-study
#3
Babak Tofighi, Frank Grazioli, Sewit Bereket, Ellie Grossman, Yindalon Aphinyanaphongs, Joshua David Lee
BACKGROUND AND OBJECTIVES: Missed visits are common in office-based buprenorphine treatment (OBOT). The feasibility of text message (TM) appointment reminders among OBOT patients is unknown. METHODS: This 6-month prospective cohort study provided TM reminders to OBOT program patients (N = 93). A feasibility survey was completed following delivery of TM reminders and at 6 months. RESULTS: Respondents reported that the reminders should be provided to all OBOT patients (100%) and helped them to adhere to their scheduled appointment (97%)...
August 11, 2017: American Journal on Addictions
https://www.readbyqxmd.com/read/28723256/quantitative-testing-of-buprenorphine-and-norbuprenorphine-to-identify-urine-sample-spiking-during-office-based-opioid-treatment
#4
Joji Suzuki, Jennifer Zinser, Mohammed Issa, Claudia Rodriguez
BACKGROUND: Patients may spike urine samples with buprenorphine during office-based opioid treatment to simulate adherence to prescribed buprenorphine, potentially to conceal diversion of medications. However, routine immunoassay screens do not detect instances of spiking, as these would simply result in a positive result. The aim of this study was to report on the experience of using quantitative urine testing for buprenorphine and norbuprenorphine to facilitate the identification of urine spiking...
July 19, 2017: Substance Abuse
https://www.readbyqxmd.com/read/28669739/an-evidence-based-recommendation-to-increase-the-dosing-frequency-of-buprenorphine-during-pregnancy
#5
Steve N Caritis, Jaime R Bastian, Hongfei Zhang, Hari Kalluri, Dennis English, Michael England, Stephanie Bobby, Raman Venkataramanan
BACKGROUND: Dose-adjusted plasma concentrations of buprenorphine are significantly decreased during pregnancy compared with the nonpregnant state. This observation suggests that pregnant women may need a higher dose of buprenorphine than nonpregnant individuals to maintain similar drug exposure (plasma concentrations over time after a dose). The current dosing recommendations for buprenorphine during pregnancy address the total daily dose of buprenorphine to be administered, but the frequency of dosing is not clearly addressed...
October 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28571505/buprenorphine-implants-in-medical-treatment-of-opioid-addiction
#6
REVIEW
Steven Chavoustie, Michael Frost, Ole Snyder, Joel Owen, Mona Darwish, Ryan Dammerman, Victoria Sanjurjo
Opioid use disorder is a chronic, relapsing disease that encompasses use of both prescription opioids and heroin and is associated with a high annual rate of overdose deaths. Medical treatment has proven more successful than placebo treatment or psychosocial intervention, and the partial µ-opioid receptor agonist and κ-opioid receptor antagonist buprenorphine is similar in efficacy to methadone while offering lower risk of respiratory depression. However, frequent dosing requirements and potential for misuse and drug diversion contribute to significant complications with treatment adherence for available formulations...
August 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28348732/probuphine%C3%A2-buprenorphine-implant-a-promising-candidate-in-opioid-dependence
#7
REVIEW
Preeti Barnwal, Saibal Das, Somnath Mondal, Anand Ramasamy, Tanay Maiti, Arunava Saha
Opioid dependence leads to physical dependence and addiction which finally results in profound medical, psychological and social dysfunction. One of the useful medications for opioid dependence is buprenorphine, the partial opioid agonist, which is used alone or in combination with naloxone. However, buprenorphine is the victim of its own success due to its illicit use and accidental poisoning in children. Also, buprenorphine typically requires daily self-administration and its effectiveness heavily depends on patient adherence...
March 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28267837/opioid-agonist-treatment-for-patients-with-dependence-on-prescription-opioids
#8
Suzanne Nielsen, Briony Larance, Nicholas Lintzeris
Clinical Question: Are different opioid agonist treatments (eg, methadone vs buprenorphine) associated with differences in efficacy for treating prescription opioid dependence, and is long-term maintenance of opioid agonist treatment associated with differences in efficacy compared with opioid taper or psychological treatments alone? Bottom Line: For patients who are dependent on prescription opioids, long-term maintenance of opioid agonists is associated with less prescription opioid use and better adherence to medication and psychological therapies for opioid dependence compared with opioid taper or psychological treatments alone...
March 7, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28162850/examination-of-the-hepatitis-c-virus-care-continuum-among-individuals-with-an-opioid-use-disorder-in-substance-use-treatment
#9
Jennifer L Brown, Nicole K Gause, Daniel Lewis, Theresa Winhusen
BACKGROUND: Hepatitis C Virus (HCV) risk is elevated for individuals with an opioid use disorder (OUD). Routine HCV testing is recommended for high-risk individuals, including those with an injection drug use history. HCV antibody testing addresses the first step in the HCV treatment care cascade, with uptake and completion of HCV treatment among individuals with chronic HCV as the optimal care cascade endpoint. The aim of this study was to characterize self-reported HCV treatment cascade outcomes among individuals with an OUD in outpatient medication assisted treatment (MAT)...
February 2, 2017: Journal of Substance Abuse Treatment
https://www.readbyqxmd.com/read/28068780/long-acting-injectable-naltrexone-induction-a-randomized-trial-of-outpatient-opioid-detoxification-with-naltrexone-versus-buprenorphine
#10
RANDOMIZED CONTROLLED TRIAL
Maria Sullivan, Adam Bisaga, Martina Pavlicova, C Jean Choi, Kaitlyn Mishlen, Kenneth M Carpenter, Frances R Levin, Elias Dakwar, John J Mariani, Edward V Nunes
OBJECTIVE: At present there is no established optimal approach for transitioning opioid-dependent adults to extended-release injection naltrexone (XR-naltrexone) while preventing relapse. The authors conducted a trial examining the efficacy of two methods of outpatient opioid detoxification for induction to XR-naltrexone. METHOD: Participants were 150 opioid-dependent adults randomly assigned 2:1 to one of two outpatient detoxification regimens, naltrexone-assisted detoxification or buprenorphine-assisted detoxification, followed by an injection of XR-naltrexone...
May 1, 2017: American Journal of Psychiatry
https://www.readbyqxmd.com/read/27955689/the-effect-of-bundling-medication-assisted-treatment-for-opioid-addiction-with-mhealth-study-protocol-for-a-randomized-clinical-trial
#11
David H Gustafson, Gina Landucci, Fiona McTavish, Rachel Kornfield, Roberta A Johnson, Marie-Louise Mares, Ryan P Westergaard, Andrew Quanbeck, Esra Alagoz, Klaren Pe-Romashko, Chantelle Thomas, Dhavan Shah
BACKGROUND: Opioid dependence has devastating and increasingly widespread consequences and costs, and the most common outcome of treatment is early relapse. People who inject opioids are also at disproportionate risk for contracting the human immunodeficiency virus (HIV) and hepatitis C virus (HCV). This study tests an approach that has been shown to improve recovery rates: medication along with other supportive services (medication-assisted treatment, or MAT) against MAT combined with a smartphone innovation called A-CHESS (MAT + A-CHESS)...
December 12, 2016: Trials
https://www.readbyqxmd.com/read/27629823/impact-of-early-childhood-trauma-on-retention-and-phase-advancement-in-an-outpatient-buprenorphine-treatment-program
#12
Nihit Kumar, Zachary N Stowe, Xiaotong Han, Michael J Mancino
BACKGROUND: Early adverse life events such as childhood trauma have been linked to development of substance use disorders. The prevalence and impact on treatment of early childhood trauma in opioid-dependent individuals has received limited research attention. The present study examined reported childhood trauma and its relation to retention and adherence in an outpatient buprenorphine treatment program. METHODS: Medical records of individuals who completed childhood trauma questionnaire (CTQ) were reviewed to extract baseline data and demographics (N = 113)...
October 2016: American Journal on Addictions
https://www.readbyqxmd.com/read/27442456/predictors-of-early-dropout-in-outpatient-buprenorphine-naloxone-treatment
#13
David E Marcovitz, R Kathryn McHugh, Julie Volpe, Victoria Votaw, Hilary S Connery
BACKGROUND AND OBJECTIVES: Identifying predictors of early drop out from outpatient treatment of opioid use disorder (OUD) with buprenorphine/naloxone (BN) may improve care for subgroups requiring more intensive engagement to achieve stabilization. However, previous research on predictors of dropout among this population has yielded mixed results. The aim of the present study was to elucidate these mixed findings by simultaneously evaluating a range of putative risk factors that may predict dropout in BN maintenance treatment...
September 2016: American Journal on Addictions
https://www.readbyqxmd.com/read/27434441/effect-of-buprenorphine-implants-on-illicit-opioid-use-among-abstinent-adults-with-opioid-dependence-treated-with-sublingual-buprenorphine-a-randomized-clinical-trial
#14
RANDOMIZED CONTROLLED TRIAL
Richard N Rosenthal, Michelle R Lofwall, Sonnie Kim, Michael Chen, Katherine L Beebe, Frank J Vocci
IMPORTANCE: The effectiveness of buprenorphine treatment of opioid dependence is limited by suboptimal medication adherence, abuse, and diversion. OBJECTIVE: To determine whether 6-month buprenorphine implants are noninferior to daily sublingual buprenorphine as maintenance treatment for opioid-dependent patients with stable abstinence. DESIGN, SETTING, AND PARTICIPANTS: Outpatient, randomized, active-controlled, 24-week, double-blind, double-dummy study conducted at 21 US sites from June 26, 2014, through May 18, 2015...
July 19, 2016: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/27434440/improving-outcomes-for-persons-with-opioid-use-disorders-buprenorphine-implants-to-improve-adherence-and-access-to-care
#15
EDITORIAL
Wilson M Compton, Nora D Volkow
No abstract text is available yet for this article.
July 19, 2016: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/27314487/satisfaction-adherence-and-health-related-quality-of-life-with-transdermal-buprenorphine-compared-with-oral-opioid-medications-in-the-usual-care-of-osteoarthritis-pain
#16
Philip G Conaghan, Michael Serpell, Paula McSkimming, Rod Junor, Sara Dickerson
BACKGROUND: Osteoarthritis (OA) causes substantial pain and reduced health-related quality of life (HRQL). Although opioid analgesics are commonly used, the relative benefits of different opioids are poorly studied. Transdermal buprenorphine (TDB) offers an alternative to oral opioids for the treatment of moderate-to-severe chronic pain. This observational study of people with OA pain assessed satisfaction, HRQL and medication adherence. METHODS: Patients in the UK with self-reported knee and/or hip OA who had been receiving one or more of TDB, co-codamol (an oral paracetamol/codeine combination) and tramadol for at least 1 month completed an online or telephone questionnaire...
2016: Patient
https://www.readbyqxmd.com/read/27121539/design-of-a-randomized-controlled-trial-of-extended-release-naltrexone-versus-daily-buprenorphine-naloxone-for-opioid-dependence-in-norway-ntx-sbx
#17
Nikolaj Kunøe, Arild Opheim, Kristin Klemmetsby Solli, Zhanna Gaulen, Kamni Sharma-Haase, Zill-E-Huma Latif, Lars Tanum
BACKGROUND: Current guidelines for opioid dependence recommend daily maintenance of physical dependence with methadone or buprenorphine, and discourage abstinence due to the high risk of relapse and overdose. Extended-release formulations of the opioid antagonist naltrexone (XR-NTX) block heroin and other opioid agonists competitively for around 4 weeks per administration. XR-NTX thus enables opioid users to experience abstinence from opioid agonists with greatly reduced risk of overdose compared to medication-free abstinence...
April 28, 2016: BMC Pharmacology & Toxicology
https://www.readbyqxmd.com/read/27068849/factors-associated-with-non-adherence-and-misuse-of-opioid-maintenance-treatment-medications-and-intoxicating-drugs-among-finnish-maintenance-treatment-patients
#18
Essiina Launonen, Isla Wallace, Elina Kotovirta, Hannu Alho, Kaarlo Simojoki
BACKGROUND: The intravenous (IV) use of opioid maintenance treatment (OMT) medications and other intoxicating drugs among OMT patients is a challenge for many OMT units and affects treatment outcomes. The aim of this study is to examine factors associated with IV use of OMT medications and other intoxicating drugs among Finnish OMT patients. METHODS: A cross-sectional study was conducted among all Finnish OMT patients of whom 60% (n=1508) participated. The data were collected by anonymous questionnaire...
May 1, 2016: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/26948856/buprenorphine%C3%A2-%C3%A2-naloxone-plus-naltrexone-for-the-treatment-of-cocaine-dependence-the-cocaine-use-reduction-with-buprenorphine-curb-study
#19
Walter Ling, Maureen P Hillhouse, Andrew J Saxon, Larissa J Mooney, Christie M Thomas, Alfonso Ang, Abigail G Matthews, Albert Hasson, Jeffrey Annon, Steve Sparenborg, David S Liu, Jennifer McCormack, Sarah Church, William Swafford, Karen Drexler, Carolyn Schuman, Stephen Ross, Katharina Wiest, P Todd Korthuis, William Lawson, Gregory S Brigham, Patricia C Knox, Michael Dawes, John Rotrosen
AIMS: To examine the safety and effectiveness of buprenorphine + naloxone sublingual tablets (BUP, as Suboxone(®) ) provided after administration of extended-release injectable naltrexone (XR-NTX, as Vivitrol(®) ) to reduce cocaine use in participants who met DSM-IV criteria for cocaine dependence and past or current opioid dependence or abuse. METHODS: This multi-centered, double-blind, placebo-controlled study, conducted under the auspices of the National Drug Abuse Treatment Clinical Trials Network, randomly assigned 302 participants at sites in California, Oregon, Washington, Colorado, Texas, Georgia, Ohio, New York and Washington DC, USA to one of three conditions provided with XR-NTX: 4 mg/day BUP (BUP4, n = 100), 16 mg/day BUP (BUP16, n = 100, or no buprenorphine (placebo; PLB, n = 102)...
August 2016: Addiction
https://www.readbyqxmd.com/read/26796596/methadone-buprenorphine-and-preferences-for-opioid-agonist-treatment-a-qualitative-analysis
#20
Bobbi Jo H Yarborough, Scott P Stumbo, Dennis McCarty, Jennifer Mertens, Constance Weisner, Carla A Green
BACKGROUND: Patients and clinicians have begun to recognize the advantages and disadvantages of buprenorphine relative to methadone, but factors that influence choices between these two medications remain unclear. For example, we know little about how patients' preferences and previous experiences influence treatment decisions. Understanding these issues may enhance treatment engagement and retention. METHODS: Adults with opioid dependence (n=283) were recruited from two integrated health systems to participate in interviews focused on prior experiences with treatment for opioid dependence, knowledge of medication options, preferences for treatment, and experiences with treatment for chronic pain in the context of problems with opioids...
March 1, 2016: Drug and Alcohol Dependence
keyword
keyword
119232
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"